BioLife Solutions 過去の業績
過去 基準チェック /06
BioLife Solutionsは15.8%の年平均成長率で業績を伸ばしているが、Life Sciences業界はdecliningで3.8%毎年増加している。売上は減少しており、年平均5.6%の割合である。
主要情報
15.81%
収益成長率
18.08%
EPS成長率
| Life Sciences 業界の成長 | 21.51% |
| 収益成長率 | -5.62% |
| 株主資本利益率 | -3.01% |
| ネット・マージン | -11.03% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • Jan 22
BLFS: New Biopreservation Center Will Support Stronger Margins And Future Returns
Analysts have nudged their price target for BioLife Solutions higher to align with a fair value estimate of about US$32.44 per share, up from roughly US$31.30. This adjustment reflects updated assumptions around slightly lower revenue growth, a modestly higher discount rate, stronger profit margins, and a somewhat lower future P/E multiple.Seeking Alpha • Oct 01
BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Summary After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses that it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing. While the shares are not cheap, revenue growth is likely at 20%+ as more client therapies become commercial. Read the full article on Seeking Alpha分析記事 • Sep 06
BioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...分析記事 • Aug 09
Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 04
Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...新しいナラティブ • May 28
Expanding Cell And Gene Therapy Workflows Will Shape Future Opportunities
Market leadership in cell and gene therapy, combined with expanded high-value product offerings, drives strong revenue and margin growth opportunities.分析記事 • Apr 30
An Intrinsic Calculation For BioLife Solutions, Inc. (NASDAQ:BLFS) Suggests It's 44% Undervalued
Key Insights BioLife Solutions' estimated fair value is US$44.43 based on 2 Stage Free Cash Flow to Equity BioLife...分析記事 • Apr 03
With BioLife Solutions, Inc. (NASDAQ:BLFS) It Looks Like You'll Get What You Pay For
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...分析記事 • Jan 24
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Dec 15
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 27% after a shaky period...分析記事 • Nov 30
Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of...分析記事 • Nov 15
Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
BioLife Solutions, Inc. ( NASDAQ:BLFS ) investors will be delighted, with the company turning in some strong numbers...分析記事 • Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Key Insights BioLife Solutions' estimated fair value is US$31.49 based on 2 Stage Free Cash Flow to Equity BioLife...分析記事 • Aug 30
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it led the NASDAQCM gainers with a...分析記事 • Aug 14
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...分析記事 • Jun 20
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jun 05
A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, BioLife Solutions fair value estimate is US$24.10 BioLife...分析記事 • May 14
Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 25% after a shaky period...分析記事 • May 13
Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders will have a reason to smile today, with the analysts making...分析記事 • May 11
Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
While BioLife Solutions, Inc. ( NASDAQ:BLFS ) might not have the largest market cap around , it received a lot of...分析記事 • Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...収支内訳
収支内訳
BioLife Solutions の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 102 | -11 | 56 | 9 |
| 31 Dec 25 | 96 | -12 | 55 | 8 |
| 30 Sep 25 | 91 | -15 | 56 | 6 |
| 30 Jun 25 | 84 | -16 | 53 | 5 |
| 31 Mar 25 | 78 | -5 | 51 | 4 |
| 31 Dec 24 | 75 | -9 | 50 | 5 |
| 30 Sep 24 | 53 | 2 | 42 | 7 |
| 30 Jun 24 | 56 | -13 | 46 | 9 |
| 31 Mar 24 | 65 | -13 | 52 | 11 |
| 31 Dec 23 | 68 | -12 | 54 | 6 |
| 30 Sep 23 | 126 | -79 | 69 | 15 |
| 30 Jun 23 | 143 | -74 | 70 | 15 |
| 31 Mar 23 | 155 | -141 | 70 | 14 |
| 31 Dec 22 | 76 | 0 | 45 | 9 |
| 30 Sep 22 | 155 | -106 | 67 | 14 |
| 30 Jun 22 | 148 | -96 | 64 | 14 |
| 31 Mar 22 | 139 | -15 | 57 | 14 |
| 31 Dec 21 | 119 | -9 | 48 | 12 |
| 30 Sep 21 | 97 | 5 | 38 | 10 |
| 30 Jun 21 | 74 | 4 | 29 | 9 |
| 31 Mar 21 | 53 | -20 | 23 | 7 |
| 31 Dec 20 | 48 | 2 | 22 | 7 |
| 30 Sep 20 | 42 | 7 | 18 | 6 |
| 30 Jun 20 | 37 | 16 | 17 | 5 |
| 31 Mar 20 | 34 | 39 | 15 | 4 |
| 31 Dec 19 | 27 | -2 | 14 | 3 |
| 30 Sep 19 | 25 | -32 | 12 | 2 |
| 30 Jun 19 | 23 | -39 | 11 | 2 |
| 31 Mar 19 | 22 | -44 | 10 | 1 |
| 31 Dec 18 | 20 | -25 | 9 | 1 |
| 30 Sep 18 | 17 | 1 | 8 | 1 |
| 30 Jun 18 | 15 | 0 | 7 | 1 |
| 31 Mar 18 | 12 | -2 | 7 | 1 |
| 31 Dec 17 | 11 | -3 | 7 | 1 |
| 30 Sep 17 | 10 | -5 | 6 | 1 |
| 30 Jun 17 | 9 | -6 | 7 | 2 |
| 31 Mar 17 | 9 | -7 | 7 | 2 |
| 31 Dec 16 | 8 | -7 | 8 | 2 |
| 30 Sep 16 | 8 | -5 | 8 | 2 |
| 30 Jun 16 | 7 | -5 | 8 | 2 |
| 31 Mar 16 | 7 | -4 | 8 | 2 |
| 31 Dec 15 | 6 | -4 | 7 | 1 |
| 30 Sep 15 | 6 | -4 | 7 | 1 |
| 30 Jun 15 | 6 | -4 | 6 | 1 |
質の高い収益: BLFSは現在利益が出ていません。
利益率の向上: BLFSは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: BLFSは利益を出していないが、過去 5 年間で年間15.8%の割合で損失を削減してきた。
成長の加速: BLFSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: BLFSは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 3.8% ) と比較することは困難です。
株主資本利益率
高いROE: BLFSは現在利益が出ていないため、自己資本利益率 ( -3.01% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 00:13 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
BioLife Solutions, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Robert Wasserman | Benchmark Company |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| George Zavoico | B. Riley Securities, Inc. |